Raising the Bar for Hemophilia Management

Subject areas

This course counts toward the state boards and subject areas below.

Disclosure statements

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME, ANCC, and ACPE that require everyone in a position to control the content of a CME/NCPD/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD/CPE activity. CME/NCPD/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME/NCPD/CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

Guy Young, MD, discloses that he has served as a consultant for Alnylam, ASC Therapeutics, Bayer, BioMarin, CSL Behring, Genentech/Roche, HEMA Biologics, Novo Nordisk, Octapharma, Pfizer, Sanofi, Spark, and Takeda; and that he has received grants/research support from HEMA Biologics and Sanofi. 

Robert F. Sidonio, Jr., MD, MSc, discloses that he has served on an advisory board or panel for Bayer, HEMA Biologics/LFB, Hemab, Novo Nordisk, Octapharma, Pfizer, Sanofi/Sobi, Star, and Takeda; that he has served as a consultant for Bayer, HEMA Biologics/LFB, Hemab, Novo Nordisk, Octapharma, Pfizer, Sanofi/Sobi, Star, and Takeda; and that he has received grants/research support from HEMA Biologics/LFB, Octapharma, and Takeda.

The i3 Health planners, reviewers, and managers have nothing to disclose.

i3 Health has mitigated all relevant financial relationships.